Literature DB >> 21269252

Targeting focal adhesion kinase in neuroblastoma.

Lauren Gillory1, Elizabeth A Beierle.   

Abstract

Neuroblastoma is the most common extracranial solid tumor encountered in children, and continues to carry a dismal prognosis. Focal adhesion kinase (FAK) has been shown to be upregulated in a number of human tumors and is related to tumor virulence and patient prognosis. We have demonstrated FAK expression in human neuroblastoma cell lines and tumors, and have shown that FAK is important for neuroblastoma tumor cell viability. We have also demonstrated that FAK inhibition through a number of different methods results in decreased neuroblastoma survival both in vitro and in vivo. The current review addresses the merit of further exploring FAK inhibition as a novel treatment for neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21269252      PMCID: PMC3225183          DOI: 10.2174/187152010794728684

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  53 in total

1.  The role of cellular motility in the invasion of human neuroblastoma cells with or without N-myc amplification and expression.

Authors:  Y Zaizen; S Taniguchi; S Suita
Journal:  J Pediatr Surg       Date:  1998-12       Impact factor: 2.545

2.  Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance.

Authors:  P S Leventhal; E A Shelden; B Kim; E L Feldman
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

3.  Concomitant down-regulation of expression of integrin subunits by N-myc in human neuroblastoma cells: differential regulation of alpha2, alpha3 and beta1.

Authors:  R Judware; L A Culp
Journal:  Oncogene       Date:  1997-03-20       Impact factor: 9.867

4.  N-myc down regulates neural cell adhesion molecule expression in rat neuroblastoma.

Authors:  R Akeson; R Bernards
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

Review 5.  Gene profiling of high risk neuroblastoma.

Authors:  Sanjeev A Vasudevan; Jed G Nuchtern; Jason M Shohet
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

6.  Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.

Authors:  L Schweigerer; S Breit; A Wenzel; K Tsunamoto; R Ludwig; M Schwab
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

7.  Role of tyrosine phosphorylation in matrix-induced neurite outgrowth in human neuroblastoma cells.

Authors:  C Bozzo; P Defilippi; L Silengo; G Tarone
Journal:  Exp Cell Res       Date:  1994-09       Impact factor: 3.905

Review 8.  Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s.

Authors:  H J Terpe; H Christiansen; M Gonzalez; F Berthold; F Lampert
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

9.  Over-expression of transfected N-myc oncogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit.

Authors:  R Judware; L A Culp
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

10.  Inverse expressions of the N-myc oncogene and beta 1 integrin in human neuroblastoma: relationships to disease progression in a nude mouse model system.

Authors:  R Judware; R Lechner; L A Culp
Journal:  Clin Exp Metastasis       Date:  1995-03       Impact factor: 5.150

View more
  1 in total

1.  The Netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-β1 and focal adhesion kinase activation.

Authors:  Andrea A Villanueva; Pilar Sanchez-Gomez; Ernesto Muñoz-Palma; Sofía Puvogel; Bárbara S Casas; Cecilia Arriagada; Isaac Peña-Villalobos; Pablo Lois; Manuel Ramírez Orellana; Fabiana Lubieniecki; Fernando Casco Claro; Iván Gallegos; Javier García-Castro; Vicente A Torres; Verónica Palma
Journal:  Cell Adh Migr       Date:  2021-12       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.